For Inquiries, please contact:
Individuals interested in participating in the clinical trial, please visit:
We have recently and repeatedly received public feedback that numerous unscrupulous individuals have been misusing the Academia Sinica logo, falsely claiming that their products are the research and development achievements of Academia Sinica Researcher Dr. Wen-Ching Yang, and selling diabetes treatment products of unknown origin while claiming...
(January 28, 2022) Pharmasaga announced that its blockbuster novel drug for Type 2 Diabetes, PS-001, has passed review by the U.S. Food and Drug Administration (FDA). This approval allows the drug to proceed into a Phase I Single-Ascending Dose (SAD) clinical trial. The Company anticipates completing the Investigational New Drug (IND)...
Jan 30
[2021.1] Pharmasaga Founding
Pharmasaga was established in January 2021 as a spin-off startup company from Academia Sinica.
The Future Tech Exhibition (FUTEX) in 2020 was held from September 24 to September 26, 2020, featuring over 600 participating startup teams. We were greatly honored that PS1, our developed First-in-Class diabetes drug, received the prestigious Future Tech Award, earning recognition from many domestic experts. We believe that in the near future, PS1...